Number of shares and voting rights of Innate Pharma as of June 1, 2023
Innate Pharma highlights Phase 1/2 dose escalation safety and preliminary efficacy of Sanofi developed first NK Cell Engager SAR'579 / IPH6101 in R/R AML
Innate Pharma to participate in upcoming investor conferences
Innate Pharma to present IPH6501 preclinical data at the EHA 2023 congress
Outcome of Innate Pharma’s 2023 Annual General Meeting
Innate Pharma Reports First Quarter 2023 Financial Results And Business Update
Number of shares and voting rights of Innate Pharma as of May 1, 2023
Innate Pharma highlights clinical abstracts selected for ASCO 2023 annual meeting
Innate Pharma announces conference call and webcast for Q1 business update
Innate Pharma establishes a new At-The-Market ("ATM") program on Nasdaq
